Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

Ozdemir Z. N., Kircali E., Şahin U., Seval G., Bozdağ S. C., Toprak S. K., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.22, sa.8, ss.596-600, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 8
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.clml.2022.02.007
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.596-600
  • Anahtar Kelimeler: Ph-acute lymphoblastic leukemia, Pre-transplant consolidation therapy, Allogeneic hematopoietic stem cell transplantation, First complete remission, Myeloablative conditioning, STEM-CELL TRANSPLANTATION, IMPROVED SURVIVAL
  • Ankara Üniversitesi Adresli: Evet

Özet

The benefit of pre-transplant consolidation treatments remains unclear in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, 57 patients with ALL who underwent allo-HSCT with myeloablative conditioning in first complete remission were evalu-ated. Overall survival was significantly better in patients receiving >= 2 consolidation compared to patients who receiving < 2 consolidation (P = 0.03). Backround and aim: The benefit of pre-transplant consolidation in patients with acute lymphoblastic leukemia (ALL) who achieved first complete remission (CR1) has not yet been clearly demonstrated. Here, we aimed to investigate the relationship between the treatments received before transplantation and transplant outcome in Ph-ALL patients who underwent myeloablative allo-HSCT in CR1. Patients and Methods: A total of 55, 32 (58.2%) men and 23 (41.8%) women, who underwent allo-HSCT with the diagnosis of Ph-ALL were evaluated retrospectively. All patients underwent to allo-HSCT with myeloablative conditioning regimen in the 1st CR from the available donor. Results: In patients who received >= 2 consolidation, the 2-year and 3-year OS was 69% and 65%, respectively, while the 2-year and 3-year OS was 39% and 26%, respectively, in those who received < 2 consolidation (P = .03). RFS was similar in both groups (P = .8). One year-NRM was found 28% in patients who received >= 2 consolidations, and 37% in patients who received < 2 consolidation (P = .06). L-asparaginase, high dose methotrexate, and cranial treatments given before transplantation had no effect on transplant outcomes (P > .05). Conclusion: Contrary to the belief that pre-transplant consolidation is not beneficial in ALL patients who proceed with allo-HCST in CR1, our results showed that consolidation treatments reduce NRM and improve the survival. (C) 2022 Elsevier Inc. All rights reserved.